GRAVITAS-309: A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Phase of Trial: Phase III
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Itacitinib (Primary) ; Methylprednisolone; Prednisone
- Indications Graft-versus-host disease
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms GRAVITAS-309
- Sponsors Incyte Corporation
- 29 Oct 2019 According to an Incyte Corporation media release, results from the study are expected in 2021.
- 11 Feb 2019 Status changed from not yet recruiting to recruiting.
- 22 Jan 2019 According to an Incyte Corporation media release, results are expected in 2019.